[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pelvic-tumor\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pelvic-tumor":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,79],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100646735","daily-adjustment-of-the-radiation-dose-in-mri-guided-stereotactic-radiotherapy-for-tumors-in-the-abdominal-and-pelvic-regions-100646735",false,"NCT07687147","Daily Adjustment of the Radiation Dose in MRI-guided Stereotactic Radiotherapy for Tumors in the Abdominal and Pelvic Regions","Adaptive Fractionation in Online MR-guided SBRT for Abdominal and Pelvic Target Volumes","ACTION","Inclusion Criteria:\n\n* Karnofsky performance status ≥70\n* Abdominal or pelvic malignancy (primary or secondary) with previous histological confirmation of the primary tumour, amenable to SBRT in 5 fractions (excluding SBRT to primary tumour in patients with prostate cancer) Note: patients with primary prostate cancer are eligible, but SBRT to the primary tumour in the prostate cannot be performed within the study\n* Total prescribed SBRT dose \\> 30 Gy (constraint for dose-limiting OAR) over 5 treatment fractions\n* Distance of the GTV ≤ 1 cm from at least one dose-limiting OAR (bowel \u002F duodenum \u002F stomach) in the available diagnostic images\n* Patients able to tolerate long (approximately 60 minutes) treatment time according to clinical evaluation of the treating radiation oncologist\n* Patients willing and able to comply with scheduled visits, treatment, and other trial procedures\n\nExclusion Criteria:\n\n* Previous radiation therapy directly overlapping with planned SBRT (type I re-irradiation)\n* More than one PTV irradiated in the same plan\n* Contraindications for MRI, e.g., patients with metal fragments or implanted devices that are not MR compatible such as certain types of pacemakers and aneurysm clips or severe claustrophobia\n* SBRT not indicated or not possible\n* Inability to follow the procedures of the trial, e.g. due to language problems of the participant","ALL","18 Years",{"count":20,"type":21},100,"ESTIMATED","INTERVENTIONAL",[24],"NA","SBRT delivers high-dose radiation to precisely defined target volumes and is an effective locally ablative treatment option for both primary tumours and oligometastases in various settings, including lesions in the abdomen or pelvis. However, SBRT in these regions faces considerable challenges such as inter-fractional organ motion and anatomical deformation, which can compromise treatment precision.\n\nMR-guided SBRT offers a solution, providing superior soft-tissue contrast and enabling real-time, online treatment plan adaptation over the course of SBRT. This approach reduces the risk of geographical miss and overdose to adjacent, vulnerable OARs. Currently, MR-guided SBRT uses a fixed dose per fraction, only adjusting target volume and OAR contours for anatomical changes when performing plan adaptation. However, overlaps between planning target volumes (PTVs) and dose-limiting OARs regularly require compromises in PTV coverage. To address this, AF aims to also adjust dose per fraction based on daily PTV-OAR overlap. With this approach, more dose is applied on treatment days with less PTV-OAR overlap while less dose is applied on days with more PTV-OAR overlap. This trial assesses the feasibility of AF in MR-guided SBRT for abdominal and pelvic tumours that show PTV-overlap with one or more dose-limiting OARs, ultimately aiming to enhance PTV dose coverage without increasing toxicity.",[27,28],"Abdominal Tumor","Pelvic Tumor",[30,31,32,33],"adaptive radiotherapy","stereotactic body radiotherapy","SBRT","MR-guided radiotherapy","RECRUITING","2026-06-29",{"date":37,"type":38},"2026-07-07","ACTUAL",{"date":40,"type":38},"2026-06-16",{"date":42,"type":21},"2028-12",{"name":44,"class":45},"University of Zurich","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":46},"100548226","contribution-of-3d-modeling-in-surgical-management-of-pediatric-retroperitoneal-and-pelvic-tumors-100548226","NCT06418243","Contribution of 3D Modeling in Surgical Management of Pediatric Retroperitoneal and Pelvic Tumors","Non-interventional Study on the Contribution of 3D Modelling in Surgical Management of Pediatric Retroperitoneal and Pelvic Tumors Compared to 2D Imaging","3D-PEDSURG","Inclusion Criteria:\n\nChildren:\n\n* Children between 3 months and less than 18 years old\n* Children with a pelvic tumor requiring an MRI for a possible surgical intervention\n* Children with a retroperitoneal tumor requiring a CT scan or MRI with a view to surgical intervention\n* Children with no contraindication for a CT scan and\u002For 3T MRI\n* Children whose parents do not object to their participation in the study\n\nOther participants:\n\n* Operating surgeon agreeing to participate in the study\n* Caregiver agreeing to participate in the study\n* External surgeon agreeing to participate in the study\n\nExclusion Criteria:\n\nChildren :\n\n* Contraindication to MRI: metallic ocular foreign body, pacemaker, mechanical heart valve, old vascular clips on cerebral aneurysm\n* Need for an MRI under general anaesthesia\n* Contraindication for a CT scan with injection: renal failure, allergy to iodinated contrast products\n* Patients having participated in a therapeutic clinical trial involving a new molecule within 30 days before inclusion\n* Emergency situation","3 Months","17 Years",{"count":58,"type":21},60,"OBSERVATIONAL","This study's purpose is the comparison of the automatically segmented 3D model to the reference manual segmentation, based on the Dice precision index. It is implemented by making parents' patients, surgeons and surgical helpers answer specific questions comparing 3D images to usual 2D images of the patient's tumor.",[28,62],"Retroperitoneal Tumor",[64,65,66,67,68,69],"Surgery","3D-Imaging","MRI","CT Scan","Paediatric surgery","Tumor","2026-03-19",{"date":72,"type":38},"2026-03-23",{"date":74,"type":38},"2024-09-16",{"date":76,"type":21},"2026-09",{"name":78,"class":45},"Assistance Publique - Hôpitaux de Paris",{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":87,"targetDuration":89,"studyType":59,"phases":4,"briefSummary":90,"conditions":91,"keywords":93,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":46},"100530306","pelvic-cancer-registry-for-online-adapted-radiotherapy-100530306","NCT06185062","Pelvic Cancer Registry for Online Adapted Radiotherapy","Pelvic and Thoracic Cancer Treated With Online Adapted Radiotherapy: A Prospective Registry-based Phase-II Trial","PRoART","INCLUSION CRITERIA\n\n* Patients with pelvic or thoracic tumors with an indication for radiotherapy\n* Patient information and declaration of consent\n* Patients age ≥ 18 years\n\nEXCLUSION CRITERIA\n\n* Prior radiotherapy in affected site",{"count":88,"type":21},846,"5 Years","This prospective registry-based trial will include patients with pelvic or thoracic tumors with an indication for radiotherapy treated with oART or IGRT. For the primary endpoint and the secondary clinical endpoints, the trial will compare oART versus IGRT, for technical endpoints the trial will compare the real oART scenario with two virtual (hypothetical) control scenarios.\n\nPrimary endpoint:\n\n* 10% reduction in the rate of acute radiotherapy related toxicity (≥ CTCAE II°, v5.0) using oART\n\nSecondary endpoints:\n\n* Clinical endpoints: Tumor control, late toxicities compared to conventional irradiated patients, quality of life and patient-reported outcomes\n* Technical endpoints: Target volume, target coverage, dose to organs at risk, anatomical variability score",[28,92],"Thoracic Tumor",[94],"online Adaptive Radiotherapy","2024-02-06",{"date":97,"type":38},"2024-02-08",{"date":99,"type":38},"2024-01-01",{"date":101,"type":21},"2030-04",{"name":103,"class":45},"University Medical Center Goettingen"]